Crizanlizumab is a medicine under development for the preventative treatment of SCD painful crisis. Circulating platelets (type of cells in the blood that has a role in blood clotting and stopping of bleeding) in SCD patients express higher levels of P-selectin, a protein that drives the blockage of blood vessels. Crizanlizumab acts by blocking P-selectin and thus can prevent blockage in small blood vessels and maintain blood flow. Therefore, if licensed, crizanlizumab will offer a new treatment option for patients with sickle cell-related pain crises.
Voxelotor is as an oral, once-daily therapy that is being developed for treatment of SCD. It is designed to work by helping haemoglobin hold onto more oxygen as the red blood cells travel through the body.